Study on Using SBRT and Atezolizumab for Treating Recurrent, Persistent, or Metastatic Cervical Cancer

Inclusion Criteria

• Must be 18 years or older.
• Have a performance status that allows for daily activities with some limitations.
• Have cervical cancer that has returned, persisted, or spread, including specific types like squamous cell, adenocarcinoma, and adenosquamous cancer, or p16+ cell cancer of the vagina or vulva.
• Have measurable cancer that can be tracked using scans or clinical exams.
  • Previously treated areas can be included if the cancer has clearly grown since the last treatment.
  • Measurable tumors must be at least 1 cm in size as seen on scans or exams.
• Have at least two separate tumors as shown by imaging tests within four weeks before starting the study.
• Agree to a biopsy of the cancer or allow access to previous tissue samples.

Exclusion Criteria

• Have known cancer spread to the brain.
• Have active autoimmune diseases or immune deficiencies, such as lupus, rheumatoid arthritis, or multiple sclerosis, with some exceptions:
  • Patients with controlled hypothyroidism on hormone replacement are eligible.
  • Patients with controlled type 1 diabetes on insulin are eligible.
• Have had another cancer within the last two years, except for certain low-risk cancers like non-melanoma skin cancer or early-stage uterine cancer.
• Are taking or need to take medications that suppress the immune system, like steroids or certain other drugs, within two weeks before starting the study, with some exceptions:
  • Patients who have taken a short course of low-dose immunosuppressants or a single high dose for a specific reason.
  • Patients on certain medications for conditions like asthma or low blood pressure.